All In Biotech

Drug Trial Radar · NCT04654390

The Efficacy Nad Safety of DWP16001 Compared to Active Drug in the Treatment of Type 2 Diabetes Mellitus

A Multi-center, Randomized, Double-Blind, Active-controlled, Phase3, Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of DWP16001 in Patients With Type 2 Diabetes Mellitus

Last checked: Nov 19, 2026Latest source record: Apr 1, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 270 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

270

Actual

Start

Dec 30, 2020

Primary completion

Dec 17, 2021

Study completion Dec 17, 2021

Sponsor

Sponsor type
Industry
First posted
Dec 4, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the efficacy and safety of DWP16001 compared to active drug in the treatment of type 2 diabetes mellitus.

Conditions

  • T2DM (Type 2 Diabetes Mellitus)

Interventions

  • DWP16001 AmgDrug

    Tablets, Orally, Once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Visit 2(Randomization) in HbA1c level at Week 24 after administation of the IPTime frame: at Week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Catholic University of Korea Bucheon St. Mary's Hospital, Republic of Korea

    Bucheon-si, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.